Top Page
Chemring (CHG) vs. S&P 500 (SPY)
Chemring Business Overview & Revenue Model
Chemring Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 483.90M | 510.40M | 472.60M | 442.80M | 393.30M | 402.50M | Gross Profit |
| 483.90M | 510.40M | 472.60M | 442.80M | 393.30M | 402.50M | EBIT |
| 39.90M | 58.10M | 45.40M | 53.30M | 50.40M | 46.30M | EBITDA |
| 62.40M | 82.70M | 67.10M | 71.20M | 75.50M | 75.10M | Net Income Common Stockholders |
| 3.10M | 39.50M | 5.40M | 47.40M | 41.50M | 34.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 19.80M | 45.00M | 6.40M | 19.80M | 5.80M | 14.70M | Total Assets |
| 620.10M | 692.10M | 596.40M | 620.10M | 531.50M | 541.40M | Total Debt |
| 26.90M | 97.70M | 20.70M | 26.90M | 32.30M | 62.80M | Net Debt |
| 7.10M | 52.70M | 14.30M | 7.10M | 26.50M | 48.10M | Total Liabilities |
| 202.00M | 335.80M | 217.90M | 202.00M | 178.70M | 211.80M | Stockholders Equity |
| 418.10M | 356.30M | 378.50M | 418.10M | 352.80M | 329.60M |
| Cash Flow | Free Cash Flow | ||||
| 12.20M | 11.40M | 31.70M | 46.00M | 45.50M | 35.10M | Operating Cash Flow |
| 68.40M | 81.00M | 65.90M | 80.50M | 75.70M | 75.90M | Investing Cash Flow |
| -57.10M | -47.60M | -39.40M | -30.50M | -34.90M | -25.40M | Financing Cash Flow |
| -27.00M | -37.30M | -40.20M | -35.80M | -50.40M | -32.10M |
Chemring Technical Analysis
Chemring Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £6.78B | 27.67 | 10.84% | 2.19% | 3.13% | 13.36% | |
75 Outperform | £1.08B | 28.31 | 11.62% | 1.76% | 8.00% | 674.47% | |
74 Outperform | $47.04B | 24.13 | 17.85% | 1.92% | ― | ― | |
72 Outperform | $62.29B | 24.56 | ― | ― | ― | ||
62 Neutral | $8.11B | 13.34 | 1.17% | 3.02% | 4.16% | -15.14% |
Chemring Corporate Events
Chemring Group PLC announced that Sarah Ellard, a director of the company, has sold 27,445 ordinary shares, retaining an interest in 233,000 shares. This transaction is part of the public disclosure requirements for persons discharging managerial responsibilities, reflecting transparency in the company’s operations.
Chemring Group PLC, a company involved in the defense and aerospace industry, has announced the purchase of 20,883 of its ordinary shares through Investec Bank plc, as part of a share buyback program initiated on February 26, 2025. The shares were bought at prices ranging from 380.50 pence to 390.00 pence per share, with a weighted average price of 386.4270 pence. The company plans to cancel the purchased shares, which is a strategic move that may impact its stock value and shareholder equity.
Chemring Group PLC has announced its capital structure as of February 28, 2025, consisting of 273,115,575 ordinary shares with voting rights and 62,500 cumulative preference shares without voting rights. This information is crucial for shareholders to determine their reporting requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their investments in the company.
Chemring Group PLC has announced the purchase of 58,159 of its ordinary shares through Investec Bank plc, as part of a buyback program initiated on February 26, 2025. The shares were acquired at prices ranging from 371.50 to 380.00 pence, with a weighted average price of 377.3103 pence. The company plans to cancel these shares, which could potentially enhance shareholder value by reducing the number of shares outstanding and improving earnings per share.
Chemring Group PLC has announced the grant of long-term incentive awards to its directors, Michael Ord, James Mortensen, and Sarah Ellard, under the company’s Long Term Incentive Plan. These conditional awards, which involve ordinary shares, are set to vest on December 18, 2027, contingent on continued service and performance conditions. This move, disclosed in the company’s 2024 annual report and approved at the recent Annual General Meeting, reflects Chemring’s commitment to aligning leadership incentives with long-term company performance, potentially impacting its operational focus and stakeholder confidence.
Chemring Group PLC has announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 8.17%. This adjustment in holdings reflects a slight increase from the previous 8.15%, indicating BlackRock’s continued interest and investment in Chemring. The change in voting rights could influence future company decisions and strategies, impacting stakeholders and potentially affecting Chemring’s market positioning within the defense and security sector.
Chemring Group PLC, a company involved in the defense and aerospace industry, has announced the repurchase of 4,654 ordinary shares through Investec Bank plc, with the intention to cancel these shares. This move is part of a buyback program announced on February 26, 2025, aimed at optimizing the company’s capital structure and potentially enhancing shareholder value.
Chemring Group PLC announced that all resolutions proposed at its Annual General Meeting on 26 February 2025 were passed with the required majority through a poll vote. This outcome reflects strong shareholder support for the company’s strategic direction and governance, potentially reinforcing its position in the defense and security sector. The resolutions, which included both ordinary and special resolutions, will be submitted to the National Storage Mechanism for public inspection.
Chemring Group PLC announced an optimistic outlook for FY25, with its order book reaching a record £1,351 million, reflecting strong customer demand across its sectors. The company is well-positioned for future growth, supported by significant orders and a new £40 million share buyback program. The Group’s strategic focus on expanding capacity and capability aligns with the increasing market opportunities, particularly in light of heightened NATO defense spending and European defense production coordination. This strategic direction aims to achieve annual revenue of approximately £1 billion by 2030, with mid-teen margins in the medium term.
Chemring Group PLC, a UK-based company, has announced a change in the voting rights held by BlackRock, Inc., a major shareholder. On February 24, 2025, BlackRock’s total voting rights in Chemring decreased from 8.51% to 8.15%, with direct voting rights at 7.04% and indirect rights through financial instruments at 1.11%. This adjustment in BlackRock’s holdings could influence Chemring’s shareholder dynamics and potentially impact its strategic decisions.
Chemring Group PLC, a UK-based company, announced a change in voting rights due to BlackRock, Inc.’s acquisition or disposal of shares. The notification indicates that BlackRock now holds 8.51% of the voting rights in Chemring, an increase from 7.86%. This change could influence Chemring’s shareholder dynamics and affect decision-making processes within the company.
Chemring Group PLC has announced its capital structure as of January 31, 2025, which comprises 273,107,974 ordinary shares with voting rights and 62,500 cumulative preference shares without voting rights except in limited cases. This information is crucial for shareholders to determine their reporting obligations under the FCA’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and regulatory compliance.
Chemring Group PLC has announced the publication of its 2024 Annual Report and Accounts, along with the Notice of its 2025 Annual General Meeting (AGM). These documents are now available to shareholders and can be downloaded from the company’s website. The AGM is scheduled to take place on February 26, 2025, in London. This announcement ensures transparency and compliance with regulatory requirements, reinforcing Chemring’s commitment to governance and stakeholder engagement.
Roke, a Chemring subsidiary, has secured a multi-year agreement with a major US Prime Contractor to supply its high-speed Miniature Radar Altimeter (MRA), marking a significant achievement in its strategy to expand revenue from its defense products. The contract, valued at £26 million over four years, underscores Roke’s growing role in space and missile programs, enhancing Chemring’s industry positioning and potentially offering substantial medium-term opportunities worth over £300 million.
Chemring Group PLC has updated its capital and voting rights structure as of December 31, 2024, with a total of 273,084,035 ordinary shares having voting rights and 62,500 cumulative preference shares lacking voting rights except in specific circumstances. This update is relevant for shareholders to assess their interest in compliance with the FCA’s Disclosure and Transparency Rules, impacting shareholder notifications and transparency obligations.
Chemring Group PLC has announced the issuance of 571,620 new Ordinary Shares, which have been submitted for listing on the FCA’s Official List and trading on the LSE’s Main Market. This issuance is part of the deferred consideration for an acquisition made in December 2022, and the new shares will be fully paid and rank equally with existing shares, potentially strengthening the company’s market position and operational capacity.
Chemring Group PLC announced the vesting of 133,726 ordinary shares to director Sarah Ellard under the company’s Performance Share Plan, with the remaining shares of the award lapsing. To cover tax and national insurance liabilities, 63,167 shares were sold on her behalf at the London Stock Exchange. This transaction highlights the company’s commitment to transparency in its executive compensation practices and could influence stakeholder perception regarding corporate governance.
Chemring Group PLC announced a significant update regarding share dealings involving James Mortensen, a director. A conditional award of 79,665 ordinary shares, granted last year, vested partially, resulting in 77,776 shares. To address tax obligations, 36,739 shares were sold on the open market. This transaction highlights the company’s ongoing compliance with share dealing regulations and the management of executive compensation, potentially impacting stakeholders’ perception of corporate governance.
Chemring Group PLC announced the vesting of 83,481 deferred ordinary shares to Michael Ord, a director, as part of his annual bonus for the year ending October 2021. Of these, 39,434 shares were sold to cover tax and national insurance liabilities, with the transaction occurring on the London Stock Exchange. This move reflects the company’s ongoing executive compensation practices, impacting stakeholders by aligning management interests with shareholder value.
Chemring Group PLC, a leader in the defense industry, revealed that an award of 255,555 ordinary shares was partially vested for Michael Ord, a director, under the Performance Share Plan. Of these, 117,852 shares were sold to cover tax liabilities. This transaction, disclosed as part of regulatory requirements, reflects the company’s commitment to transparency and its structured approach to executive compensation.
Chemring Group PLC announced the vesting of 35,795 deferred ordinary shares to Sarah Ellard, a company director, as part of her annual bonus for the fiscal year ending October 2021. Of these, 16,909 shares were sold to cover tax and national insurance liabilities, reflecting standard corporate governance practices and maintaining transparency in executive compensation and share dealings.
Chemring Group PLC announced the issuance of 84,262 deferred ordinary shares to Michael Ord, a company director, as part of his annual bonus for the 2024 fiscal year. This award, which is set to vest in three years, underscores Chemring’s commitment to rewarding its leadership, potentially enhancing managerial retention and aligning their interests with the company’s long-term performance.
Chemring Group PLC has announced the grant of a conditional award of 138,876 ordinary shares to Sarah Ellard, a director, under its Performance Share Plan 2016. This award is part of the company’s incentive scheme, which aims to align the interests of management with stakeholders by linking compensation to performance metrics, with a vesting period of three years and an additional holding period of two years.
Chemring Group PLC has announced the grant of an award of 45,011 deferred ordinary shares to James Mortensen, a company director, as part of his annual bonus for the financial year ending 31 October 2024. This move reflects Chemring’s commitment to aligning management incentives with shareholder interests, potentially impacting the company’s strategic direction and stakeholder relations.
Chemring Group PLC has announced the grant of 35,422 deferred ordinary shares to Sarah Ellard, a company director, as part of her annual bonus for the year ending October 2024. The deferred share award, which is set to vest in three years, highlights Chemring’s approach to rewarding its leadership and may influence its managerial incentive structures.
Chemring Group PLC has granted a conditional award of 275,294 ordinary shares to director Michael Ord under its 2016 Performance Share Plan. The shares, which require no payment upon vesting, will vest in three years contingent on performance conditions and continued service, followed by a two-year holding period. This move highlights the company’s commitment to aligning managerial incentives with performance, potentially impacting its strategic direction and stakeholder engagement.
Chemring Group PLC has announced a conditional award of 176,470 ordinary shares to James Mortensen, a director, under its Performance Share Plan 2016. This award is part of the company’s incentive schemes and will vest after three years, contingent on continued service and meeting performance conditions, with an additional two-year holding period post-tax vesting. This move is indicative of Chemring’s commitment to aligning management interests with shareholder value, showcasing strategic focus on long-term performance and stability.
Chemring Group PLC announced that directors Tony Wood and James Mortensen have purchased 15,000 and 9,125 shares, respectively, in the company. These transactions underscore the confidence of the company’s leadership in its financial prospects, potentially influencing stakeholder perceptions and market positioning.
Chemring Group PLC reported a robust performance for the year ending 31 October 2024, with an 8% revenue increase attributed to strong growth in its specialist energetic materials businesses and Roke division. Despite facing operational challenges, the company achieved a record order book, providing excellent medium-term revenue coverage. The company invested significantly in expanding capacity, particularly in Norway, amidst increased global demand. The outlook for global defense markets remains strong, and Chemring aims to achieve annual revenue of approximately £1 billion by 2030, positioning itself for sustained growth and value creation.